A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus

نویسندگان
akhavan rezayat arash ID 1
auso perez jose ramon ID 2
borjkhani mehdi ID 3
faria daniel ID 4
thatcher robert w ID 5
hedayati mojtaba ID 6
fatehi farangis ID 7

1 دانشگاه علوم پزشکی شیراز

2

3 دانشگاه صنعتی ارومیه

4

5 دانشگاه علوم توانبخشی و سلامت اجتماعی

6 دانشگاه علوم پزشکی گیلان

7 دانشگاه علوم پزشکی شهید صدوقی

doi
10.5812/archcid.107788
چکیده

Since late 2019, when novel coronavirus pneumonia emerged in China and spread worldwide, there has been a need for data concerning the clinical characteristics of infected immunocompromised patients. It has been reported that a significant mortality rate occurs in individuals with underlying comorbidities such as hematologic malignancies. Therefore, it is vital to illustrate the clinical manifestations and outcomes of COVID-19 in these vulnerable patients and identify safe therapeutic strategies. This study reviewed the clinical course, laboratory findings, and risk factors associated with hematologic malignant patients with COVID-19 along with the management and therapeutic regimens.

کلیدواژه‌ها
Coronavirus, COVID-19, SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2, Hematological Malignant Patients